Beata Lagiewska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Beata Lagiewska has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Marek Pacholczyk
Department of General and Transplantation Surgery, Medical University of Warsaw, Warsaw, Poland
33 shared publications - Magdalena Durlik
Warsaw Medical University, Warsaw, Poland
14 shared publications A. Chmura
Department of General and Transplantation Surgery, Warsaw Medical University, Warsaw, Poland
13 shared publications- Leszek Pączek
Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland
13 shared publications - Wojciech Lisik
Department of General and Transplantation Surgery, Medical University of Warsaw, Warsaw, Poland
12 shared publications W Rowiński
11 shared publications
Latest Publications
- Open Access
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 4 (1) , 13-27
The epidemiology of hepatocellular cancer in Poland
Introduction This article summarize the available data on hepatocellular carcinoma (HCC) epidemiology in Poland. Data regarding the HCC incidence rate are divergent. Statistical data presented by NFZ appear more credible in that matter than data published by the Polish Oncology Center (POC)....
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 4 (1) , 13-27
Open AccessThe epidemiology of hepatocellular cancer in Poland
Introduction This article summarize the available data on hepatocellular carcinoma (HCC) epidemiology in Poland. Data regarding the HCC incidence rate are divergent. Statistical data presented by NFZ appear more credible in that matter than data published by the Polish Oncology Center (POC)....
- 11 July 2017
- Published by Frontiers Media SA in Acta Biochimica Polonica
- Vol. 64 (2) , 331-337
Prognostic value of perioperative assessment of plasma cardiac troponin I in patients undergoing liver transplantation
An elevation in plasma cardiac troponin is an indicator of increased perioperative risk in orthopaedic and vascular surgery, however data on liver transplantation (LTx) are scarce.The aim of the study was to evaluate the prevalence of cardiac troponin I (cTnI) elevation in the perioperative period of LTx, and its potential relationship with 1-year mortality.Material and methods. Analysis included 79 patients with liver cirrhosis. During LTx all patients underwent hemodynamic measurements. cTnI was determined before the operation, 24, 48 and 72 hours afterwards. One-year mortality was assessed.Results. 12.7% patients died, all during in-hospital period. cTnI on day 1. was identified as the most promising marker of increased death risk with optimal cut-off value of 0.215 ng/ml (the sensitivity of 60.0%, specificity of 87.0%, positive predictive value of 40.0%, negative predictive value of 93.8%).The most important predictor of cTnI increase was the duration of the LTx procedure followed by packed red blood cells transfused, basic stroke volume index, and cardiac output index.In conclusion: value of cTnI assessed 24 hours post-surgery was a reliable predictor of death following LTx with optimal cut-off value of 0.215ng/ml. The surgery time was the most important predictor of cTnI elevation.
- 11 July 2017
- Published by Frontiers Media SA in Acta Biochimica Polonica
- Vol. 64 (2) , 331-337
Prognostic value of perioperative assessment of plasma cardiac troponin I in patients undergoing liver transplantation
An elevation in plasma cardiac troponin is an indicator of increased perioperative risk in orthopaedic and vascular surgery, however data on liver transplantation (LTx) are scarce.The aim of the study was to evaluate the prevalence of cardiac troponin I (cTnI) elevation in the perioperative period of LTx, and its potential relationship with 1-year mortality.Material and methods. Analysis included 79 patients with liver cirrhosis. During LTx all patients underwent hemodynamic measurements. cTnI was determined before the operation, 24, 48 and 72 hours afterwards. One-year mortality was assessed.Results. 12.7% patients died, all during in-hospital period. cTnI on day 1. was identified as the most promising marker of increased death risk with optimal cut-off value of 0.215 ng/ml (the sensitivity of 60.0%, specificity of 87.0%, positive predictive value of 40.0%, negative predictive value of 93.8%).The most important predictor of cTnI increase was the duration of the LTx procedure followed by packed red blood cells transfused, basic stroke volume index, and cardiac output index.In conclusion: value of cTnI assessed 24 hours post-surgery was a reliable predictor of death following LTx with optimal cut-off value of 0.215ng/ml. The surgery time was the most important predictor of cTnI elevation.
- 1 June 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (5) , 1855-1857
Delayed, Uncommon Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Case Report
- 1 June 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (5) , 1855-1857
Delayed, Uncommon Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Case Report
- 17 December 2015
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 20, 747-751
Is Hydroxyethyl Starch Irrelevant to Hemostasis in Patients Undergoing Liver Transplantation? – In vitro Analysis Based on Thromboelastometry
Liver transplantation may be associated with severe bleeding that requires intensive fluid management. Aggressive fluid administration could result in hemodilution, triggering dilutional coagulopathy that intensifies bleeding. Colloids are plasma expanders used in daily practice. Fibrinogen, malfunctioning in liver cirrhosis, is the earliest decreasing clotting factor while bleeding. Fibrinogen supplementation is recommended as the first-choice therapy in such cases. Therefore, the influence of hemodilution on fibrin clot formation among patients with liver cirrhosis was analyzed, followed by the assessment of fibrinogen supplementation in clot restitution. Blood collected from 22 patients with post-inflammatory liver cirrhosis was diluted up to 30% and 60% with crystalloid (0.9% NaCl) or colloid (6% hydroxyethyl starch 130/0.4), followed by fibrinogen supplementation corresponding to an overall dose of 4 g. The influence of hemodilution on plasma fibrinogen concentration and on thromboelastometry FIBTEM test was analyzed, as well as the influence of fibrinogen supplementation. Hemodilution lowers fibrinogen concentration and decreases fibrin clot formation. The higher the grade of dilution, the more profound the disturbances observed; 6% hydroxyethyl starch 130/0.4 cause more intense effect on fibrin clot formation than 0.9% NaCl. Fibrinogen supplementation improves fibrin clot formation as assessed in FIBTEM. Fibrinogen supplementation among patients with liver cirrhosis might improve fibrin clot formation during hemodilution. Fibrinogen supplementation might by considered as a possible treatment of coagulopathy during liver transplantation, but further clinical studies need to be performed.
- 17 December 2015
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 20, 747-751
Is Hydroxyethyl Starch Irrelevant to Hemostasis in Patients Undergoing Liver Transplantation? – In vitro Analysis Based on Thromboelastometry
Liver transplantation may be associated with severe bleeding that requires intensive fluid management. Aggressive fluid administration could result in hemodilution, triggering dilutional coagulopathy that intensifies bleeding. Colloids are plasma expanders used in daily practice. Fibrinogen, malfunctioning in liver cirrhosis, is the earliest decreasing clotting factor while bleeding. Fibrinogen supplementation is recommended as the first-choice therapy in such cases. Therefore, the influence of hemodilution on fibrin clot formation among patients with liver cirrhosis was analyzed, followed by the assessment of fibrinogen supplementation in clot restitution. Blood collected from 22 patients with post-inflammatory liver cirrhosis was diluted up to 30% and 60% with crystalloid (0.9% NaCl) or colloid (6% hydroxyethyl starch 130/0.4), followed by fibrinogen supplementation corresponding to an overall dose of 4 g. The influence of hemodilution on plasma fibrinogen concentration and on thromboelastometry FIBTEM test was analyzed, as well as the influence of fibrinogen supplementation. Hemodilution lowers fibrinogen concentration and decreases fibrin clot formation. The higher the grade of dilution, the more profound the disturbances observed; 6% hydroxyethyl starch 130/0.4 cause more intense effect on fibrin clot formation than 0.9% NaCl. Fibrinogen supplementation improves fibrin clot formation as assessed in FIBTEM. Fibrinogen supplementation among patients with liver cirrhosis might improve fibrin clot formation during hemodilution. Fibrinogen supplementation might by considered as a possible treatment of coagulopathy during liver transplantation, but further clinical studies need to be performed.
- 1 January 2015
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 20, 112-115
The First Polish Liver Transplantation after Roux-en-Y Gastric Bypass Surgery for Morbid Obesity: A Case Report and Literature Review
Morbid obesity is associated with liver pathology, most commonly non-alcoholic steatohepatitis (NASH) leading to cirrhosis. However, the morbid obesity impedes qualification for organ transplantation. We present a case report of a 56-year-old woman who underwent bariatric procedure followed by liver transplantation (LTx). Her initial weight was 130.2 kg (BMI 50.9 kg/m2). The patient had a history of arterial hypertension, diabetes, gonarthrosis, and obstructive sleep apnea syndrome and no history of alcohol abuse. She underwent Roux-en-Y gastric bypass (RYGB) procedure. The routine intraoperative liver biopsy revealed fibrosis (III°), steatosis (II°), and intra-acinar inflammation. The operation led to a substantial loss of weight. Two years after the surgery the patient was referred to the Transplantation Clinic of Department of General Surgery and Transplantology with suspicion of liver failure due to advanced cirrhosis, which could be a result of previously diagnosed NASH and, probably, excessive alcohol use after bariatric surgery. The patient was qualified for elective LTx, which was performed 3 years after the RYGB. Immediately before LTx, the patient's weight was 65 kg (BMI 25.4 kg/m²). The postoperative period was complicated by bleeding into the peritoneal cavity, which required reoperation. She also had renal failure, requiring renal replacement therapy. One year after LTx, she showed stable liver function with normal transaminases activity and bilirubin concentration, remission of diabetes, and good renal function. Steatohepatitis in morbidly obese patients may lead to cirrhosis. Bariatric procedure can be a bridge to liver transplantation for morbidly obese patients with advanced liver fibrosis.
- 1 January 2015
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 20, 112-115
The First Polish Liver Transplantation after Roux-en-Y Gastric Bypass Surgery for Morbid Obesity: A Case Report and Literature Review
Morbid obesity is associated with liver pathology, most commonly non-alcoholic steatohepatitis (NASH) leading to cirrhosis. However, the morbid obesity impedes qualification for organ transplantation. We present a case report of a 56-year-old woman who underwent bariatric procedure followed by liver transplantation (LTx). Her initial weight was 130.2 kg (BMI 50.9 kg/m2). The patient had a history of arterial hypertension, diabetes, gonarthrosis, and obstructive sleep apnea syndrome and no history of alcohol abuse. She underwent Roux-en-Y gastric bypass (RYGB) procedure. The routine intraoperative liver biopsy revealed fibrosis (III°), steatosis (II°), and intra-acinar inflammation. The operation led to a substantial loss of weight. Two years after the surgery the patient was referred to the Transplantation Clinic of Department of General Surgery and Transplantology with suspicion of liver failure due to advanced cirrhosis, which could be a result of previously diagnosed NASH and, probably, excessive alcohol use after bariatric surgery. The patient was qualified for elective LTx, which was performed 3 years after the RYGB. Immediately before LTx, the patient's weight was 65 kg (BMI 25.4 kg/m²). The postoperative period was complicated by bleeding into the peritoneal cavity, which required reoperation. She also had renal failure, requiring renal replacement therapy. One year after LTx, she showed stable liver function with normal transaminases activity and bilirubin concentration, remission of diabetes, and good renal function. Steatohepatitis in morbidly obese patients may lead to cirrhosis. Bariatric procedure can be a bridge to liver transplantation for morbidly obese patients with advanced liver fibrosis.
- 1 October 2014
- Published by Elsevier in Transplantation Proceedings
- Vol. 46 (8) , 2777-2781
Bacterial and Fungal Infections in the Early Post-transplantation Period After Liver Transplantation: Etiologic Agents and Their Susceptibility
- 1 October 2014
- Published by Elsevier in Transplantation Proceedings
- Vol. 46 (8) , 2777-2781
Bacterial and Fungal Infections in the Early Post-transplantation Period After Liver Transplantation: Etiologic Agents and Their Susceptibility
- 1 January 2013
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 18, 651-653
Liver transplantation for nonresectable metastatic solid pseudopapillary pancreatic cancer
Solid pseudopapillary tumor (SPT) of the pancreas, also known as Franz tumor, Hamoudie tumor, solid-cystic-papillary epithelial neoplasm, or solid and cystic tumor, is a neoplasm of transitory (potential) malignancy, seen predominantly in young women. This report presents a female patient treated for a solid pseudopapillary tumor of the pancreas with hepatic metastases. The tumor was first diagnosed in 2006. Non-specific abdominal pain was the first presenting symptom. The patient underwent distal pancreatic resection and splenectomy in July 2006. Multifocal metastatic disease seen at surgery precluded radical resection. Following definitive pathology confirmation and the exclusion of extrahepatic metastases, the patient was referred to our transplant centre 18 months after pancreatic surgery, to be considered for orthotopic liver transplantation (OLTx). The extent of the disease was once again evaluated by imaging studies, followed by exploratory laparotomy. The patient underwent cadaveric liver transplantation in March 2008, with triple immunosuppression (tacrolimus, MMF, and steroids) following surgery. Presently, more than 5 years post-transplant, the patient has no signs of recurrent neoplasmatic disease. This is the first liver transplantation for a metastatic pancreatic pseudopapillary tumor in Poland, with the longest follow-up period described in the literature. Follow-up suggests a cautiously optimistic prognosis despite primary unresectability of hepatic metastases and the necessity for immunosuppressive therapy.
- 1 January 2013
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 18, 651-653
Liver transplantation for nonresectable metastatic solid pseudopapillary pancreatic cancer
Solid pseudopapillary tumor (SPT) of the pancreas, also known as Franz tumor, Hamoudie tumor, solid-cystic-papillary epithelial neoplasm, or solid and cystic tumor, is a neoplasm of transitory (potential) malignancy, seen predominantly in young women. This report presents a female patient treated for a solid pseudopapillary tumor of the pancreas with hepatic metastases. The tumor was first diagnosed in 2006. Non-specific abdominal pain was the first presenting symptom. The patient underwent distal pancreatic resection and splenectomy in July 2006. Multifocal metastatic disease seen at surgery precluded radical resection. Following definitive pathology confirmation and the exclusion of extrahepatic metastases, the patient was referred to our transplant centre 18 months after pancreatic surgery, to be considered for orthotopic liver transplantation (OLTx). The extent of the disease was once again evaluated by imaging studies, followed by exploratory laparotomy. The patient underwent cadaveric liver transplantation in March 2008, with triple immunosuppression (tacrolimus, MMF, and steroids) following surgery. Presently, more than 5 years post-transplant, the patient has no signs of recurrent neoplasmatic disease. This is the first liver transplantation for a metastatic pancreatic pseudopapillary tumor in Poland, with the longest follow-up period described in the literature. Follow-up suggests a cautiously optimistic prognosis despite primary unresectability of hepatic metastases and the necessity for immunosuppressive therapy.
- 1 January 2012
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 17 (4) , 5-10
Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience
Currently, HCV (hepatitis C virus) cirrhosis is one of the most common indications for liver transplantation (LTx) in Europe and North America among adults. Very early after LTx, histological examinations of liver biopsies in a group of HCV-positive recipients show important differences compared to other indications for transplantation. We described results of 121 primary LTx for HCV cirrhosis. HCV-RNA PCR was positive in 94% of primary graft recipients prior to LTx. Co-existing HCC was diagnosed in 20.66% of recipients. One-year, 5-year, and 10-year survivals in the HCV-positive recipient group were 87.6%, 85.9%, and 84.3%, respectively. Symptomatic recurrent hepatitis was diagnosed in 58/121 (47.54%) recipients, and 41.3% presented with recurrence within the first 6 months. None of the PCR-negative recipients developed recurrent hepatitis prior to LTx. The rescue therapy for recurrent HCV hepatitis consist of Interferon and Ribavirin; the sustained virologic response (SVR) was obtained in 50% and 41% of recipients at 24 and 48 weeks, respectively, after treatment cessation. Despite almost universal recurrence of HCV after LTx, results of transplantation are relatively good. Modification of immunosuppression, younger organ selection, and avoiding steroid pulses for rejection improve the results. Inclusion of combination therapy with interferon and Ribavirin allows for more than 40% SVR.
- 1 January 2012
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 17 (4) , 5-10
Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience
Currently, HCV (hepatitis C virus) cirrhosis is one of the most common indications for liver transplantation (LTx) in Europe and North America among adults. Very early after LTx, histological examinations of liver biopsies in a group of HCV-positive recipients show important differences compared to other indications for transplantation. We described results of 121 primary LTx for HCV cirrhosis. HCV-RNA PCR was positive in 94% of primary graft recipients prior to LTx. Co-existing HCC was diagnosed in 20.66% of recipients. One-year, 5-year, and 10-year survivals in the HCV-positive recipient group were 87.6%, 85.9%, and 84.3%, respectively. Symptomatic recurrent hepatitis was diagnosed in 58/121 (47.54%) recipients, and 41.3% presented with recurrence within the first 6 months. None of the PCR-negative recipients developed recurrent hepatitis prior to LTx. The rescue therapy for recurrent HCV hepatitis consist of Interferon and Ribavirin; the sustained virologic response (SVR) was obtained in 50% and 41% of recipients at 24 and 48 weeks, respectively, after treatment cessation. Despite almost universal recurrence of HCV after LTx, results of transplantation are relatively good. Modification of immunosuppression, younger organ selection, and avoiding steroid pulses for rejection improve the results. Inclusion of combination therapy with interferon and Ribavirin allows for more than 40% SVR.
- 1 October 2011
- Published by Elsevier in Transplantation Proceedings
- Vol. 43 (8) , 3052-3054
Urinary Tract Infections in the Early Posttransplant Period After Liver Transplantation: Etiologic Agents and Their Susceptibility
- 1 October 2011
- Published by Elsevier in Transplantation Proceedings
- Vol. 43 (8) , 3052-3054
Urinary Tract Infections in the Early Posttransplant Period After Liver Transplantation: Etiologic Agents and Their Susceptibility